文献速递咽喉与嗓音

环杓侧肌注射A型肉毒毒素治疗咳嗽的疗效

Efficacy of Botulinum A Injection to the Laryngeal Adductor Compartment for Treatment of Cough.
PubMed 文献 · Laryngoscope · 2023-09-29

回顾性分析2012年6月至2022年6月47例接受经皮环杓侧肌A型肉毒毒素注射治疗的咳嗽患者,共197次注射,69.8%的注射获得主观改善,咳嗽严重程度指数平均变化为-2.12,提示总体改善;VHI-10无变化,吞咽困难发生15次(7.6%),无吸入性肺炎或住院。

要点

  • 69.8%的注射获得患者主观咳嗽改善,咳嗽严重程度指数平均下降2.12。
  • 有主观改善者ΔCSI为-4.43,无改善者为+2.68,二者差异有统计学意义。
  • 吞咽困难发生于15次注射(7.6%),无吸入性肺炎或住院。

核心结论

  • 环杓侧肌A型肉毒毒素注射可能有效治疗咳嗽,且严重并发症风险有限。

研究设计与样本

  • 回顾性研究,纳入2012年6月至2022年6月接受经皮环杓侧肌A型肉毒毒素注射治疗咳嗽的患者47例,共197次注射。

主要发现

  • 有主观改善者估计ΔCSI为-4.43,无主观改善者为+2.68(P<0.0001)。
  • VHI-10无变化(0.69,P=0.483)。
  • 肺部疾病与声带活动受限均与主观改善或ΔCSI无相关性;吞咽困难发生于15次注射(7.6%),无吸入性肺炎或住院。

关键数值与推荐

  • 有主观改善者估计ΔCSI为-4.43,无主观改善者为+2.68(P<0.0001)。
  • VHI-10变化为0.69(P=0.483)。

临床怎么用

  • 作者认为环杓侧肌A型肉毒毒素注射可能有效治疗咳嗽,且严重并发症风险有限。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Studies examining electromyography (EMG)-guided laryngeal onobotulinumtoxinA (BTxA) injection for chronic cough reveal promising efficacy, however, are limited by small cohorts and absent quantifiable outcomes. It further remains unclear if pulmonary disease limits efficacy, or if vagal motor neuropathy prognosticates response. We hypothesize BTxA injection results in qualitative improvement in cough, decrease in Cough Severity Index (CSI), no change in Voice Handicap Index-10 (VHI-10), and complication rates comparable to historical data. We also examine the correlation of pulmonary comorbidities and vocal fold hypomobility with treatment efficacy. STUDY DESIGN: Retrospective review. METHODS: Charts for patients receiving percutaneous adductor compartment BTxA injection for cough were reviewed for the binary outcome of patient-reported presence or absence of improvement. Generalized estimating equations regression models were used to analyze the change in CSI (ΔCSI) and the correlation of ΔCSI with qualitative outcomes. Multivariable analyses were used to examine correlation of vocal fold hypomobility and pulmonary disease with qualitative outcomes and ΔCSI. RESULTS: Forty-seven patients underwent 197 BTxA injections from June 2012 to June 2022. A statistical proportion of 0.698 (0.599-0.813, p < 0.0001) or 69.8% of injections resulted in subjective improvement. Mean ΔCSI was -2.12 (0.22-4.02, p < 0.05), indicating overall improvement. With and without subjective improvement, estimated ΔCSI was -4.43 and +2.68, respectively (p < 0.0001). VHI-10 did not change (0.69, p = 0.483). Neither pulmonary disease nor vocal fold hypomobility correlated with subjective improvement or ΔCSI. Dysphagia occurred following 15 (7.6%) injections with no aspiration pneumonia or hospitalization. CONCLUSIONS: BTxA injection to the laryngeal adductors may effectively treat cough with limited risk for serious complications. LEVEL OF EVIDENCE: 4 Laryngoscope, 134:1749-1756, 2024.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Campbell BA, Flormann VB, Davis RB, et al. Efficacy of Botulinum A Injection to the Laryngeal Adductor Compartment for Treatment of Cough. Laryngoscope. 2023. PMID: 37772912. doi:10.1002/lary.31072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。